Management of blood glucose in type 2 diabetes mellitus

American Family Physician

Volumn 79, Issue 1, 2009, Pages

  Ripsin, Cynthia M ^a,b   Kang, Helen ^a   Urban, Randall J ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETYLSALICYLIC ACID; ALPHA GLUCOSIDASE; ALPHA GLUCOSIDASE INHIBITOR; AMYLIN DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EXENDIN 4; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCRETIN; INSULIN; LONG ACTING INSULIN; METFORMIN; NATEGLINIDE; PIOGLITAZONE; PRAMLINTIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; ANTIDIABETIC AGENT;

CALORIC RESTRICTION; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DRUG DOSE TITRATION; DYSLIPIDEMIA; EVIDENCE BASED PRACTICE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HOME MONITORING; HUMAN; HYPERTENSION; INSULIN RELEASE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; LOW FAT DIET; MICROALBUMINURIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; REVIEW; TREATMENT INDICATION; TREATMENT PLANNING; WEIGHT REDUCTION; ADULT; ALGORITHM; ARTICLE; BLOOD; CHILD; DIET; DRUG EFFECT; EXERCISE; LIFESTYLE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ADULT; ALGORITHMS; BLOOD GLUCOSE; CHILD; DIABETES MELLITUS, TYPE 2; DIET; EXERCISE; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; WEIGHT LOSS;

EID: 59149102061     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Centers for Disease Control and Prevention. National diabetes fact sheet - United States, 2005. http://www.cdc.gov/diabetes/pubs/pdf/ ndfs-2005.pdf. Accessed October 9, 2008.
2. Goetzel RZ, Hawkins K, Ozminkowski RJ, Wang S. The health and productivity cost burden of the "top 10" physical and mental health conditions affecting six large U.S. employers in 1999. J Occup Environ Med. 2003;45(1):5-14.
3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999;354(9178):602]. Lancet. 1998;352(9131):837-853.
4. Implications of the United Kingdom Prospective Diabetes Study. American Diabetes Association. Diabetes Care. 1998;21(12):2180-2184.
5. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [published correction appears in Lancet. 1998;352(9139):1558]. Lancet. 1998;352(9131):854-865. (Pubitemid 28416719)
6. Knowler WC, Barrett-Connor E, Fowler SE, et al., for the Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.
7. American Diabetes Association. Clinical practice recommendations 2007. Diabetes Care. 2007;30(suppl 1):S1-S103.
8. Norris SL, Zhang X, Avenell A, et al. Long-term, non-pharmacologic weight loss interventions for adults with type 2 diabetes. Cochrane Database Syst Rev. 2005;(2):CD004095.
9. Thomas DE, Elliott EJ, Naughton GA. Exercise for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2006;(3):CD002968.
10. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383-393. (Pubitemid 36159355)
11. Goodman LS, Gilman AZ, Brunton LL. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill; 2005.
12. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298(10):1189-1195. (Pubitemid 47403105)
13. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes [published correction appears in N Engl J Med. 2007;357(1):100]. N Engl J Med. 2007;356(24):2457-2471.
14. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy [published correction appears in Diabetes Care. 2006;49(11):2816-2818]. Diabetes Care. 2006;29(8):1963-1972.
15. Kimmel B, Inzucchi SE. Oral agents for type 2 diabetes: an update. Clin Diabetes. 2006;23:64-76.
16. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus [published correction appears in Ann Intern Med. 2007;147(12):887]. Ann Intern Med. 2007;147(6):386-399.
17. Uwaifo GI, Ratner RE. Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk. Am J Cardiol. 2007;99(4A):51B-67B. (Pubitemid 46251370)
18. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med. 2003;163(21):2594-2602. (Pubitemid 37464417)
19. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a metaanalysis of randomized trials. JAMA. 2007;298(10):1180-1188. (Pubitemid 47403104)
20. Chiasson JL. Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the STOP-NIDDM Trial. Endocr Pract. 2006;12(suppl 1):25-30.
21. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laasko M, for the STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. JAMA. 2003;290(4):486-494. (Pubitemid 37430502)
22. AHFS Drug Information. Exenatide (systemic). http://www.ashp.org/ mngrphs/essentials/a305021e.htm. Accessed October 9, 2008.
23. AHFS Drug Information. Sitagliptin phosphate. http://www.ashp.org/ mngrphs/AHFS/a307001.htm. Accessed October 9, 2008.
24. Hirsch IB, Bergenstal RM, Parkin CG, Wright E Jr, Buse JB. A real-world approach to insulin therapy in primary care practice. Clin Diabetes. 2005;23:78-86. (Pubitemid 40965048)
25. Farmer A, Wade A, Goyder E, et al. Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. BMJ. 2007;335(7611):132. (Pubitemid 47172232)
26. Welschen LM, Bloemendal E, Nijpels G, et al. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review. Diabetes Care. 2005;28(6):1510-1517. (Pubitemid 40756728)
27. AHFS Drug Information. Metformin hydrochloride. http://www.ashp. org/mngrphs/AHFS/a396005.htm. Accessed October 9, 2008.